medigraphic.com
ISSN 0028-3851 (Print)

2005, Number 1

Next >>

Rev Neurol Neurocir Psiquiat 2005; 38 (1)

Clinical response of intramuscular metoclopramide as compared to this one administered orally in acute migraine attacks

Salazar ZA, Bañuelos EMA, Espinoza GI

Language: Spanish
References: 20
Page: 1-6
PDF size: 106.56 Kb.


ABSTRACT

Introduction. Migraine is a primary headache or cephalea, it is typically characterized by several combinations of neurological gastrointestinal and psychophysiological changes.
Objetive. To demonstrate that metoclopramide by the intramuscular via is faster and more effective than the oral way one.
Material and Methods. A prospective, randomized, blind clinical study was done with 44 patients (39 women and 5 men) with migraine headaches, 51.3% of the patients were between the ages of 18 to 37. Each patient randomly received 10 mg of metoclopramide intramuscularly or 10 mg tablet of metoclopramide orally for the next 60 minutes. Vital signs, intensity of headache and associated symptoms were evaluated.
Results. The headache disappeared in all patients (100%) treated with intramuscular metoclopramide, and only 13 (59%) of patients treated with oral metoclopramide did it disappear within the hour.
Discussion. Adverse effects noted with intramuscular metoclopramide were: dizziness in 14.2% and somnolence in 9.5%, in those treated with oral metoclopramide adverse effects were: dizziness in 4.8%, somnolence in 4.8%, and increase in headache in 4.8%. There was not a significant difference between intramuscular and oral metoclopramide p › 0.05 at 15, 30 and 45 minutes, nevertheless at 60 minutes the response in the intramuscular group was statistically significant at p ‹ 0.01. Vital signs remained normal during the 60 minutos of observation, and were checked every 15 minutes.
Conclusion. We concluded that intramuscular metoclopramide is more effective and faster acting than the administered orally in patients with acute migraine attacks, with less adverse effects.


REFERENCES

  1. Saper JR. Diagnosis and symptomatic treatment of migraine. Headache 1997; 37: s1-s13.

  2. Salazar ZA. Cefaleas y migraña. Hospital Central Militar. Terapeútica y procedimientos medicoquirúrgicos. 1a. Ed. México, D.F.: Editores de Textos Mexicanos; 2002, p. 454-8.

  3. Colman I, Brown MD, Innes Grant D, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ 2004; 329: 1369-72.

  4. Weich KMA. Pathogenesis of migraine. Seminars in Neurology 1997; 17(4): 335-41.

  5. Frishberg MB. Neuroimaginig in presumed primary headache disorders. Seminars in Neurology 1997; 17(4): 373-81.

  6. Moskowits MA. The visceral organ brain implications for the pathophyiology of vascular head pain. Neurology 1991; 41: 182.

  7. Moscowits MA. The neurobiology of vascular head pain. Annals Neurol 1984; 16: 157.

  8. Headache classification Committee of the International Headache Society. Classification and diagnostic criteria for headache, disorders cranial neuralgias and facial pain. Cephalalgia 1988; 8(7): 1-96.

  9. Marks RD, Rappaport MA. Diagnosis of migraine. Seminars in Neurology 1997; 17(4): 303-6.

  10. Ellis GL, Delany J, et al. The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med 1993; 191-5.

  11. Mathew TN. Cluster Headache. Seminars in Neurology 1997; 17(4): 313-23.

  12. Marks RD, Rappaport MA. Practical evaluation and diagnosis of headache. Seminars in Neurology 1997; 17(4): 307-12.

  13. Mosche N, Schuarzberg MD. Application of metoclopramide specificity in migraine attacks theraphy. Headache 1994; 34: 439-41.

  14. Coppola M, et al. Randomized, placebo controlled evaluation of prochloperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med 1995; 26(5): 541-6.

  15. Salazar ZA, Esteban MA, Trujillo CHP, Rivera MCG. Respuesta clínica de metoclopramida en comparación con cumatriptan en el tratamiento de ataques agudos de migraña. Rev Sanid Milit Méx 1999; 53(1): 36-40.

  16. Moskowits MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993; 43(3): s16-s20.

  17. Klapper JA, et al. Current emergency treatment of severe migraine headaches. Headache 1993; 33: 560-2.

  18. Steward FW, et al. Migraine prevalence. Neurology 1994; 44(4): 17-23.

  19. Peroutka SJ. Dopamine and migraine. Neurology 1997; 49: 650-6.

  20. Ferrari MD. Migraine. Lancet 1998; 351: 9108: 1043-56.




2020     |     www.medigraphic.com